Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
  • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
  • A61K36/486—Millettia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
  • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/34—Alcohols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
  • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
  • A61K8/9783—Angiosperms [Magnoliophyta]
  • A61K8/9789—Magnoliopsida [dicotyledons]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/12—Aerosols; Foams
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
  • A61K2800/59—Mixtures
  • A61K2800/592—Mixtures of compounds complementing their respective functions
  • A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18

Definitions

• Cosmetic composition comprising a combination of pongamia oil and 4-t-butylcyclohexanol to combat
• the present invention relates to the following novel combination: pongamia oil and 4-t-butylcyclohexanol; and its applications in the fields of cosmetics and dermatology to fight against redness.
• the present invention relates to the cosmetic use of a composition comprising said combination for controlling rosacea.
• the skin is the organ of the largest human body, nearly 2m 2 of surface. It plays several fundamental roles, including external protection, thermal regulation, hormonal synthesis and has an immune function.
• the skin consists of three superimposed layers that are the epidermis, in permanent renewal, the dermis and the hypoderm which ensures the fibrous framework.
• the skin's color, texture and quality also have an undeniable psychosocial function.
• Sensitive skins have in common to react quickly and excessively to a change in temperature, cold, wind, irritating hygiene or toilet products, unsuitable care.
• the redness of the face is the prerogative of the sensitive skins, these skins which are distinguished by an exacerbated reactivity of the skin and cutaneous vessels.
• the redness is more or less intermittent, but always uncomfortable and embarrassing.
• Intermittent redness also called “flush” is an acute vasodilation reaction that may be due to a commonplace or a little “stressful” situation such as a questioning for a student, a hiring interview, an emotionally moving or conflictual conversation but still a temperature change that requires the circulation of blood in the face.
• a diet too hot, alcoholic beverages or certain foods can also cause this redness.
• redness can occur in people with vasoreactive skin, a cutaneous feature that may be familial or skin aging: from 25 years the skin is more sensitive to redness
• redness can become permanent, especially in the cheeks. This is called erythrosis which is a diffuse but permanent redness localized most often on the cheeks in the form of red patches.
• the rosacea represents an aggravation of the erythrose with appearance of small dilated vessels.
• Rosacea is a chronic and progressive joint inflammatory dermatosis related to vascular relaxation. It is a condition that affects the small vessels of the face. It frequently affects fair-skinned people and can have significant psycho-emotional consequences. The name of this pathology refers to the characteristic color of the face during the illness. The general appearance of the face, which incorrectly suggests a chronic excess of alcohol consumption, the Rosacea is a socially particularly difficult disease to live in, especially by women. Rosacea is a fairly common disease, since in France 2 to 3% of the adult population is concerned. Women are particularly affected, since there are two women for a man suffering from rosacea.
• Rosacea mainly affects the central part of the face and is characterized by facial redness or flushing, facial erythema, papules, pustules, telangiectasia and sometimes ocular lesions called ocular rosacea.
• facial redness or flushing facial erythema
• papules papules
• pustules pustules
• telangiectasia ocular lesions
• ocular rosacea ocular rosacea.
• the soft tissue of the nose can swell and produce bulbous swelling called rhinophyma. Rosacea evolves, but not obligatorily, over several years by exacerbations aggravated by different stimuli such as temperature variations, alcohol, spices, sun exposure or emotions.
• Erythematotelangiectatic rosacea It is mainly characterized by flushing and persistent central facial erythema. The presence of telangiectasia is common, but not essential to the diagnosis of this type. Central facial edema, burning and stinging, and roughness or desquamation are also sometimes observed.
• Papulopustular rosacea it is characterized by persistent central facial erythema and transient papules and / or pustules distributed in the center of the face. However, papules and pustules can also affect periorifical areas, such as perioral, perineal or periocular. This type of rosacea is reminiscent of acne, but comedones are absent. But rosacea and acne can coexist. Patients with this type of rosacea sometimes complain of burning and stinging. This type is often observed before or at the same time as the previous type, including the presence of telangiectasia. These may be masked by persistent erythema and papules or pustules.
• Rhinophyma it is manifested by a thickening of the skin, nodules with an irregular surface and swelling. Rhinophyma is the most common presentation, but phymatous rosacea can affect other areas, such as the chin, forehead, cheeks or ears. In patients with this type of rosacea, the presence of enlarged and prominent follicular openings is sometimes reported in the affected area, as well as telangiectasia. This type is often observed before or at the same time as types 1 or 2. In the case of rhinophyma, these additional stigmas may be particularly pronounced in the nasal region.
• Ocular or ophthalmic rosacea The diagnosis of ocular rosacea should be considered when a patient presents with one or more of the following eye signs and symptoms: tearful or bloodshot appearance, foreign body sensation, burning or stinging, dryness, itching, photosensitivity, blurred vision, telangiectasia of the conjunctiva and eyelid margin or erythema of the eyelid and periocular. Blepharitis, conjunctivitis and irregular margins of the eyelid are other signs that may be detected. A chalazion or chronic staphylococcal infection manifested by a stye and the cause of which is a malfunction of the Meibomian glands is a common sign of ocular disease associated with rosacea.
• ocular rosacea The diagnosis of ocular rosacea is most often made when cutaneous signs and symptoms are also detected.
• Corticosteroids can also be incriminated, especially in 2 situations, the first is rosacea which is aggravated by the application of corticosteroids. The second is the appearance of the disease following the long-term use of this type of medication, it is even called steroid rosacea.
• Oral treatments with tetracycline derivatives are problematic for several reasons but in particular for their non-negligible side effects.
• Oral administration of tetracyclines, such as doxycycline may induce photosensitivity, or even phototoxicity or gastrointestinal disorders.
• the application WO2002 / 074290 describes the topical use of at least one non-steroidal anti-inflammatory compound for treating rosacea, these compounds may be combined with a nitroimidazole compound.
• these compounds may be combined with a nitroimidazole compound.
• the combination of this treatment induces significant side effects, including gastrointestinal and renal (Edwards, Br. J. Vener Dis., 56, 285-290, 1980).
• the present invention thus aims to provide an effective treatment of rosacea.
• this treatment is performed topically, which significantly reduces any systemic side effect.
• the present invention therefore relates to the combination of pongamia oil and 4-t-butylcyclohexanol for use in the prevention and / or treatment of rosacea.
• the combination of pongamia oil and 4-t-butylcyclohexanol constitutes the sole active agent for the prevention and / or treatment of rosacea or for the prevention and / or treatment of cutaneous redness.
• the present invention therefore relates to the combination of pongamia oil and 4-t-butylcyclohexanol for its use in the prevention and / or treatment of cutaneous redness.
• Skin redness may be intermittent redness (ie flush), particularly localized in the cheeks or erythrosis, particularly localized in the cheeks.
• Pongamia pinnata is a tree of the Fabaceae family. It is widespread in India, Indonesia, Malaysia, Taiwan, Bangladesh, Sri Lanka, South China, Japan, East Africa, Northern Australia and North America. This tree can live in quite varied conditions, can survive temperatures of 5 ° C to 50 ° C and altitudes of 0 to 1200 m. It can grow in almost any soil type, even low in nitrogen and high in salt and tolerates drought. There is a multitude of scientific names to define this tree, which shows that this plant comes in a wide variety of forms, which have sometimes been described as different species. Pongamia is up to 18 m tall.
• the phytochemical examination of the different parts of pongamia shows the presence of specific compounds such as furanoflavones, furanoflavonols, chromenoflavones, furanodicetones.
• the seeds contain oil (27-40%), proteins (17-20%), mucilage (about 14%), amino acids and traces of an essential oil.
• Other compounds are also found, such as flavones including karanjine and pongamol, chalcones, rotenones, phenol acids, sterols.
• the oil present in tree seeds in India contains mainly oleic, linoleic, linolenic and behenic acids. While Pakistan's pongamia seed oil contains myristic, palmitic, stearic, oleic, linoleic, linolenic, arachidic, behenic and lignoceric acid. The unsaponifiable fraction is important (5.5%).
• Pongamia oil is used mainly in India for its pest control activity in both human and animal therapy, but also in agriculture to protect crops against their aggressors, insects and nematodes.
• pongamia oil is applied to the skin for eliminate the parasite from scabies. This acaricidal activity has been highly developed, it is more important when the oil is associated with ascorbic acid.
• Different extracts of pongamia oil, or seed extract, leaves or bark
• repellent activity towards harmful species for several cultivated plants indeed the pongamia extracts have proved effective on about forty harmful species.
• pongamia oil has antimicrobial activity on several bacteria of the genera Bacillus, Micrococcus, Pseudomonas, Staphylococcus, Salmonella, Sarcina, Escherichia and Xanthomonas.
• pongamia oil The acaricide activity identified for pongamia oil is the starting point for its use in rosacea. Pongamia oil is not known to have anti-inflammatory activity, nor in all cutaneous pathologies related to inflammation.
• TRPV1 transient receptor potential vanilloid 1
• TRPV1 receptors are ionotropic receptors activated by molecules of the vanilloid family such as capsaicin present in chili pepper.
• TRPV1 receptors are part of the TRP family. This family of receptors is sensitive to mechanical and thermal stimuli and certain chemical substances.
• TRPV1 are non-selective cation channel-type receptors which, in response to a stimulus, allow the entry of calcium ions in bulk.
• TRPV1 are localized at the peripheral end of small diameter sensory neurons. They are sensory receptors expressed at the level of the cutaneous envelope, mucous membranes and in certain regions of the central nervous system. They are activated by a nociceptive heat, a low pH, as well as oxidized linoleic acid metabolites synthesized during burns and in general by other substances belonging to the vallinoid family.
• the receiver is activated and changes its conformation which leads to an opening of the channel-cation.
• TRPV1 TRPV1
• 4-t-butylcyclohexanol in formulation with pentylene glycol, is marketed under the name Symsitive® 1609, it is a TRPV1 antagonist, it is stable at pH 3 to 12 and at temperatures up to 50 ° C. It is effective for small skin problems, such as tugging, tingling. On the other hand, this compound is not known to have an activity in inflammation, nor in all cutaneous pathologies related to inflammation.
• the present invention thus aims to provide a treatment of rosacea, which in particular decreases the side effects for the patient.
• this treatment is performed topically, which significantly reduces any systemic side effect.
• the subject of the present invention is therefore an association which comprises pongamia oil and 4-t-butylcyclohexanol for its use in the treatment and / or prevention of rosacea.
• 4-t-butylcyclohexanol is in trans form.
• 4-t-butylcyclohexanol is solubilized in pentylene glycol.
• 4-t-butylcyclohexanol is solubilized in octyl dodecanol.
• the present invention also relates to an association which comprises pongamia oil and 4-t-butylcyclohexanol for use in the treatment and / or prevention of rosacea, which is selected from the group consisting of erythematotelangiectatic rosacea , papulopustular rosacea, phymatous rosacea, ocular rosacea.
• 4-t-butylcyclohexanol is in trans form.
• the present invention also relates to an association which comprises pongamia oil and 4-t-butylcyclohexanol for use in the treatment and / or prevention of inflammatory diseases.
• the present invention also relates to the use of the combination comprising pongamia oil and 4-t-butylcyclohexanol for preparing a medicament for treating and / or preventing rosacea.
• 4-t-butylcyclohexanol is in trans form.
• the present invention also relates to the use of the combination comprising pongamia oil and 4-t-butylcyclohexanol to prepare a medicament for treating and / or preventing inflammatory diseases.
• the combination according to the invention is applied topically.
• the combination according to one of the embodiments of the invention is characterized in that it is in a proper form and suitable for topical application.
• topical application an application to the skin, mucous membranes and / or integuments.
• treatment means decreasing and / or inhibiting the development of rosacea or inflammatory pathologies and / or its symptoms.
• Symptoms of rosacea include persistent redness, burning and stinging, hot flashes or telangiectasia.
• the present invention also relates to the use of the combination comprising pongamia oil and 4-t-butylcyclohexanol to reduce and / or prevent redness.
• the use is preferably topically and it is a cosmetic use.
• redness is meant more particularly redness of the skin, intermittent redness of the skin (ie flushes), more particularly localized cheeks.
• the present invention thus aims at a cosmetic method for attenuating and / or preventing skin redness comprising the topical application of a combination comprising pongamia oil and 4-t-butylcyclohexanol.
• the skin rashes are located at the level of the cheeks.
• the present invention also relates to a cosmetic composition for reducing and / or preventing skin redness comprising a combination comprising pongamia oil and 4-t-butylcyclohexanol with a cosmetically acceptable excipient, more particularly acceptable for topical application.
• 4-t-butylcyclohexanol is solubilized in pentylene glycol.
• 4-t-butylcyclohexanol is solubilized in octyl dodecanol.
• the cosmetic composition according to is characterized in that the dermatologically or dermo-cosmetically acceptable excipient comprises a solvent chosen from octyl dodecanol, 1,5-pentanediol and at least one vegetable oil.
• the solvent is octyl dodecanol or 1,5-pentanediol.
• the term "cosmetically, dermatologically or dermo-cosmetically acceptable” is intended to mean what is useful in the preparation of a cosmetic, dermatological or dermo-cosmetic composition, which is generally safe, non-toxic and neither biologically nor otherwise undesirable and which is acceptable for therapeutic or cosmetic use, especially by topical application.
• compositions according to the invention may be in the forms which are usually known for topical administration, that is to say in particular lotions, foams, gels, dispersions, emulsions, sprays, serums, masks or creams, with excipients allowing in particular skin penetration to improve the properties and accessibility of the active ingredient.
• topical administration that is to say in particular lotions, foams, gels, dispersions, emulsions, sprays, serums, masks or creams, with excipients allowing in particular skin penetration to improve the properties and accessibility of the active ingredient.
• it will be a cream, an emulsion.
• the invention thus relates to dermatological or dermo-cosmetic compositions according to one of the embodiments of the present invention, characterized in that they are in their own form and adapted to a topical application.
• compositions generally contain, besides the compounds of the combination according to the present invention, a physiologically acceptable medium, generally based on water or water.
• solvent for example alcohols, ethers or glycols. They may also contain surfactants, complexing agents, preservatives, stabilizing agents, emulsifiers, thickeners, gelling agents, humectants, emollients, trace elements, essential oils, perfumes, dyes, mattifying agents, chemical or mineral filters, moisturizing agents or thermal waters, etc.
• solvent for example alcohols, ethers or glycols.
• surfactants for example alcohols, ethers or glycols. They may also contain surfactants, complexing agents, preservatives, stabilizing agents, emulsifiers, thickeners, gelling agents, humectants, emollients, trace elements, essential oils, perfumes, dyes, mattifying agents, chemical or mineral filters, moisturizing agents or thermal waters, etc.
• the invention thus relates to a combination comprising pongamia oil and 4-t-butylcyclohexanol in which the 4-t-butylcyclohexanol is solubilized in a fatty alcohol type solvent, alkane diol comprising from 3 to 20 carbon atoms, or well a vegetable oil.
• a fatty alcohol type solvent alkane diol comprising from 3 to 20 carbon atoms, or well a vegetable oil.
• the cosmetically, dermatologically or dermocosmally acceptable excipient may thus comprise at least one fatty alcohol and / or at least one alkane diol, comprising from 3 to 20 carbon atoms and / or at least one vegetable oil.
• the alkane diol may thus be selected from the group consisting of 1,2-propylene glycol, 2-methylpropane-1,3-diol, 1,2-butylene glycol, 1,3-butanediol, 1,2-pentanediol, 1,3-pentanediol, 1,5-pentanediol, 2,4-pentanediol, 2-methylpentane-2,4-diol, 1, 2-hexanediol, 1,6-hexanediol, 1,2-octanediol, dipropylene glycol preferably 1,2-butylene glycol, 1,2-pentanediol and dipropylene glycol.
• 1,5-pentanediol also called pentylene glycol.
• Fatty alcohol can be selected from the group of alcohols linear or branched fatty acids consisting of decanol, decenol, octanol, octenol, dodecanol, dodecenol, octadienol, decadienol, dodecadienol, oleyl alcohol, ricinoleyl alcohol, erucyl alcohol, stearyl alcohol, isostearyl alcohol, cetyl alcohol, lauryl alcohol, myristyl alcohol, arachidyl alcohol , linoleyl alcohol, linolenyl alcohol, hexyldecanol, octyldodecanol (especially 2-octyl-1-dodecanol), cetearyl alcohol and behenyl alcohol.
• it is octyl dodecanol.
• the invention thus relates to a combination comprising pongamia oil and 4-t-butylcyclohexanol in which 4-t-butylcyclohexanol is solubilized in a solvent selected from the group consisting of octyl dodecanol, 1,5-pentanediol and at least one vegetable oil.
• the vegetable oil can be selected from the group consisting of almond oil, peanut oil, argan oil, avocado oil, safflower oil, coconut, rapeseed oil, cottonseed oil, wheat germ oil, linseed oil, corn oil, neem oil, hazelnut oil, nuts, kernel oil, poppyseed oil, olive oil, palm oil, pumpkin seed oil, grape seed oil, castor oil, lemon rice oil, sesame oil, soybean oil, sunflower oil, microalgae oil.
• compositions according to the present invention will also comprise Avene water.
• compositions may further contain other active ingredients leading to a complementary or possibly synergistic effect.
• the compositions according to the present invention will comprise 0.01 to 5% by weight, preferably 0.05 to 2% by weight, more preferably 0.1 to 1% by weight of pongamia oil relative to the weight. total of the composition.
• the composition will comprise 0.1% by weight of pongamia oil relative to the total weight of the composition.
• the composition will comprise 0.5% by weight of pongamia oil relative to the total weight of the composition.
• compositions according to the present invention will comprise 0.01 to 5% by weight, preferably 0.05 to 2% by weight, more preferably 0.1 to 1% by weight of 4-t-butylcyclohexanol relative to total weight of the composition.
• the composition will comprise 0.1% by weight of 4-t-butylcyclohexanol relative to the total weight of the composition.
• the composition will comprise 0.5% by weight of 4-t-butylcyclohexanol relative to the total weight of the composition.
• the dermatological, dermo-cosmetic or cosmetic compositions and combinations according to the invention may comprise pongamia oil and 4-t-butylcyclohexanol in a mass ratio of 4-t-butylcyclohexanol: pongamia oil of between 1: 10 and 10: 1, plus particularly 1: 1, even more particularly 1: 5.
• the invention therefore relates to an association or a dermatological or dermo-cosmetic composition for its use in the treatment and / or prevention of rosacea as further detailed in which the mass ratio 4-t-butylcyclohexanol: pongamia oil is included between 1: 10 and 10: 1, more particularly 1: 1, even more particularly 1: 5.
• the invention also relates to an association or a cosmetic composition for its use in the treatment and / or the prevention of cutaneous redness, as further detailed, in which the mass ratio 4-t-butylcyclohexanol: pongamia oil is between 1: 10 and 10: 1, more particularly 1: 1, or even more particularly 1: 5.
• the invention also relates to an association or a cosmetic composition for the attenuation and / or prevention of cutaneous redness, as further detailed, in which the mass ratio 4-t-butylcyclohexanol: pongamia oil is between 1: 10 and 10: 1, more particularly 1: 1, even more particularly 1: 5.
• compositions may be made according to methods well known to those skilled in the art.
• Example 1 Pharmacological test of the combination of pongamia oil and 4-t-butylcyclohexanol in pentylene glycol
• the purpose of this study is to evaluate the effects of the combination of pongamia oil and 4- t-butylcyclohexanol in pentylene glycol on the inflammatory response of normal human epidermal keratinocytes in an environment of rosacea.
• the rosacea environment is mimed by the mixture of three agonists; an inflammatory mediator, an innate immunity mediator and a bacterial component selected from TNF activating agents, TLR2 receptor activating agents and TRP receptor activating agents (TRPV1, TRPA1), LL37 peptide as described in Steinhoff et al., 2013, JAAD.
• the pongamia oil is evaluated at 10 g / ml (corresponding to 0.001%), the pentylene glycol 4-t-butylcyclohexanol is evaluated at 300 ⁇ (corresponding to 47 g / ml of 4-t-butylcyclohexanol, and therefore at 0, 0047%).
• An IKK inhibitor evaluated at ⁇ was used as a positive control.
• IL8 production is quantified by ELISA according to the supplier's instructions (R & D Systems). A percentage inhibition of the secretion of IL8 after exposure to the various compounds tested is calculated. Statistical analysis is performed using one-way analysis of variance (ANOVA) followed by Dunnett's test.
• Pentolysis 4-t-butylcyclohexanol at 300 ⁇ statistically significantly inhibits IL8 production.
• Pongamia oil at 10 g / ml weakly inhibits IL8 secretion but still in a statistically significant manner.
• the combination of pentylene glycol-4-t-butylcyclohexanol and pongamia oil at the same concentrations as above inhibits the secretion of IL8 more than with the compounds taken alone, whether with pentylene 4-t-butylcyclohexanol glycol (P ⁇ 0.05) or pongamia oil (p ⁇ 0.001).
• the inventors have demonstrated a real synergy on the inhibition of IL8 production with the combination of pentylene glycol 4-t-butylcyclohexanol and pongamia oil. With such activity, this combination has very promising soothing and calming properties.
• Example 2 Example of Composition According to the Invention
• Example 3 Example of Composition According to the Invention

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Dermatology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Birds (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Mycology (AREA)
• Biotechnology (AREA)
• Botany (AREA)
• Microbiology (AREA)
• Inorganic Chemistry (AREA)
• Medical Informatics (AREA)
• Alternative & Traditional Medicine (AREA)
• Dispersion Chemistry (AREA)
• Emergency Medicine (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Rheumatology (AREA)
• Pain & Pain Management (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Cosmetics (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Plant Substances (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=58669934

Family Applications (1)

Country Status (8)

Families Citing this family (4)

Family Cites Families (8)

• 2017
  • 2017-01-04 FR FR1750059A patent/FR3061434B1/fr active Active
  • 2017-12-22 WO PCT/EP2017/084456 patent/WO2018127435A1/fr unknown
  • 2017-12-22 EP EP17829204.1A patent/EP3565569A1/fr not_active Withdrawn
  • 2017-12-22 CN CN201780087770.6A patent/CN110392576B/zh active Active
  • 2017-12-22 BR BR112019013824A patent/BR112019013824B8/pt active IP Right Grant
  • 2017-12-22 US US16/475,988 patent/US10765641B2/en active Active
  • 2017-12-22 KR KR1020197022244A patent/KR102585914B1/ko active IP Right Grant
  • 2017-12-22 JP JP2019556733A patent/JP7206216B2/ja active Active

Also Published As

Similar Documents

Legal Events